Open Access. Powered by Scholars. Published by Universities.®
Immunology and Infectious Disease Commons™
Open Access. Powered by Scholars. Published by Universities.®
Articles 1 - 1 of 1
Full-Text Articles in Immunology and Infectious Disease
The Broad-Spectrum Antiviral Favipiravir Protects Guinea Pigs From Lethal Lassa Virus Infection Post-Disease Onset, David Safronetz, Kyle Rosenke, Jonna B. Westover, Cynthia Martellaro, Atsushi Okumura, Yousuke Furuta, Joan Geisbert, Greg Saturday, Takashi Komeno, Thomas W. Geisbert, Heinz Feldmann, Brian B. Gowen
The Broad-Spectrum Antiviral Favipiravir Protects Guinea Pigs From Lethal Lassa Virus Infection Post-Disease Onset, David Safronetz, Kyle Rosenke, Jonna B. Westover, Cynthia Martellaro, Atsushi Okumura, Yousuke Furuta, Joan Geisbert, Greg Saturday, Takashi Komeno, Thomas W. Geisbert, Heinz Feldmann, Brian B. Gowen
Plants, Soils, and Climate Faculty Publications
With up to 500,000 infections annually, Lassa virus (LASV), the cause of Lassa fever, is one of the most prevalent etiological agents of viral hemorrhagic fever (VHF) in humans. LASV is endemic in several West African countries with sporadic cases and prolonged outbreaks observed most commonly in Sierra Leone, Liberia, Guinea and Nigeria. Additionally several cases of Lassa fever have been imported into North America, Europe and Asia making LASV a global threat to public health. Despite this, currently no approved therapeutic or vaccine exists to treat or prevent LASV infections. Here, using a passaged strain of LASV that is …